KDM6B and cerebral infarction: Other researchers have demonstrated that miR-22-3p within extracellular vesicles derived from adipose mesenchymal stem cells could alleviate ischaemic injury by inhibiting the lysine-specific demethylase 6B/bone morphogenetic protein 2/Bcl-2 modifying factor (KDM6B/BMP2/BMF) pathway (see Figure 3) reducing the volume of cerebral infarction and promoting the recovery of neural mechanisms (49).